ArticleEndocrine, metabolic & immune disorders drug targets2026
Guipi Decoction Attenuates Fibrosis and Oxidative Stress to Ameliorate Diabetic Erectile Dysfunction in Rats via the RhoA/ROCK Signaling Pathway
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to investigate whether Guipi Decoction ameliorates Diabetic Erectile Dysfunction (DMED) in rats by regulating the RhoA/ROCK signaling pathway.
methods36 SD rats were utilized: 6 served as controls, and 30 were induced into DMED models using STZ, confirmed by blood glucose >16.7 mmol/L and a failed erection test. Successfully modeled DMED rats were divided into five groups (n=6/group): Model (saline), Sildenafil (5 mg/kg), and GD Low (0.5 g/mL), Medium (1 g/mL), and High (2 g/mL) dose groups. All groups received corresponding treatments for 4 weeks. Assessments included: body weight, FBG, lipids (TC, TG), erectile function (ICP/MAP ratio), penile NO levels, renal function (BUN, SCr), oxidative stress markers (SOD activity, MDA content), penile histopathology (HE and Masson staining), and mRNA/protein expression levels of RhoA, ROCK1, ROCK2, Caspase-3, p-LIMK2, and p-MYPT1, analyzed via qPCR, Western blot, and IHC.
resultsCompared with controls, DMED model rats showed significantly elevated FBG, TG, TC, BUN, SCr, and MDA levels, as well as upregulated expression of RhoA/ROCK pathway-related proteins and Caspase-3 (all P<0.01). In contrast, their body weight, ICP/MAP ratio, NO levels, SOD activity, and penile smooth muscle/collagen ratio were significantly reduced (all P<0.01). GD treatment exerted significant dose-dependent effects: relative to the Model group, GD increased the ICP/MAP ratio, NO levels, and SOD activity (all P<0.01); decreased FBG, weight loss, TC, TG, BUN, SCr, and MDA levels (P<0.05 or P<0.01); improved erectile function; alleviated penile fibrosis and pathological damage; and downregulated the mRNA and protein expression of RhoA, ROCK1, ROCK2, Caspase-3, p-LIMK2, and p-MYPT1 (P<0.05 or P<0.01). Higher GD doses showed stronger therapeutic efficacy. DISCUSSION: he therapeutic effects of GD on DMED may be attributed to its ability to inhibit the RhoA/ROCK signaling pathway, which in turn enhances NO bioavailability, mitigates oxidative stress (as reflected by increased SOD activity and decreased MDA content), and suppresses apoptosis (via reduced Caspase-3 expression).
conclusionGuipi Decoction effectively improves erectile function and ameliorates penile histopathological lesions in DMED rats, suggesting its potential as a therapeutic agent for DMED through modulation of the RhoA/ROCK signaling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.